"GB Sciences Inc. Adds Provisional Nevada Recreational Cannabis License for Branded Recreational Products"
GB Sciences Will Bring Medical-Grade Cannabis to the Recreational Use Market by Introducing Cultivation Labs™ Branded Products
LAS VEGAS, July 10, 2017 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) has added its own medical-grade retail brand to its already strong portfolio, which includes granted-medical and provisional-recreational use Nevada cultivation licenses and patent-pending medical formulations.
The decision to sell to the recreational market through the addition of GB Sciences' own trusted-ingredient retail brands, strengthens the Company's vertically-integrated strategy of controlling product quality and purity from seed-to-sale. Premium flower and medical-grade oils for use in vape pens and tinctures will be sold under the Cultivation Labs banner.
On July 1st, Nevada joined Colorado, Oregon, Washington, and Alaska, to become the fifth state to legalize the use of recreational cannabis. Expectations ran high for the state given its international entertainment destination, Las Vegas. This city hosts forty-two million visitors annually – many of whom will take advantage of the new law. Dispensaries reported long lines with forty-five minute waits and extended hours. One such dispensary, ReLeaf, reported 1000 customers per day vs. a previous count of only 100-150 customers per day. The Nevada Dispensary Association reported three million in sales revenue for this four-day holiday weekend.
John Poss, CEO, GB Sciences, remarked: "The arrival of recreational sales in Nevada presents a unique and well-timed opportunity for GB Sciences. It will allow the Company to self-fund the research and development of our medical formulations, while building a globally trusted brand for recreational users. What better city than Las Vegas to show the world that the quality and purity of medical grade ingredients can and should be demanded in recreational products. We look forward to satisfying this demand for every visitor that comes to town."
About GB Sciences, Inc.
GB Sciences, Inc. (GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, medical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.